about the author

Brittany Meiling

editors@endpointsnews.com
Brittany Meiling on LinkedIn

author articles

Zai Lab bombs Phase IIa tri­al in atopic der­mati­tis, junks the pro­gram to shift re­sources to the pipeline

7 years ago
R&D

A new av­enue for di­et pill mak­ers? UC San Diego re­searchers un­cov­er root of lep­tin re­sis­tance

7 years ago
Discovery

Once laud­ed for its clin­i­cal suc­cess, Roche casts off car­dio pro­gram in­clacum­ab for a mere $2M to Glob­al Blood ...

7 years ago
Pharma

Mag­ic mush­rooms might treat de­pres­sion? Pe­ter Thiel-backed Com­pass gets FDA OK to launch Phase IIb tri­als

7 years ago
Startups

Jaun­dice drug for in­fants re­ject­ed by FDA, shak­ing up Mallinck­rodt's plans for new­ly-ac­quired stannso­porfin

7 years ago
R&D

Shrink the pa­tient group, boost the ef­fi­ca­cy: Tonix says a retro look shows promise in se­lect PTSD group

7 years ago
R&D

A knock­down-and-re­place gene ther­a­py from Penn re­searchers shows promise in rare eye dis­ease

7 years ago
Cell/Gene Tx

Novo's new tri­al re­sults stoke block­buster hopes, with oral semaglu­tide scor­ing again in Phase II­Ia

7 years ago
R&D

Hous­ing As­traZeneca's old R&D ef­forts in an­tibi­otics, En­ta­sis files for $86M IPO

7 years ago
Financing

Out­spo­ken re­searcher Pe­ter Bach urges CMS to con­sid­er ways of bring­ing down CAR-T prices — and of­fers a few ...

7 years ago
Pharma

Months af­ter team­ing up on RTK in­hibitor Lenvi­ma, Ei­sai/Mer­ck win new FDA OK in liv­er can­cer

7 years ago
Pharma

'Gap years' are for adults, too: Ex-Foun­da­tion ex­ec Steve Kaf­ka joins Third Rock af­ter glo­be­trot­ting break

7 years ago
People

Ar­mored CAR-Ts? Memo­r­i­al Sloan Ket­ter­ing en­gi­neers CAR-T loaded with check­point in­hibitors

7 years ago
Discovery

Eyes on Chi­na stocks: Lon­car loads new ETF with his picks for most promis­ing biotechs on HKEX and Nas­daq

7 years ago
China
Pharma

Bil­lion­aire-backed Ju­ve­nes­cence spins out an­ti-ag­ing, AI start­up Na­pa Ther­a­peu­tics

7 years ago
Financing
Startups

Ex-Pfiz­er ex­ec Geno Ger­mano joins nanopar­ti­cle start­up Elu­ci­da On­col­o­gy as CEO

7 years ago
People

Pfiz­er On­col­o­gy los­es its CMO to Al­ler­gan as can­cer ex­ec Charles Hugh-Jones makes a ca­reer leap

7 years ago
People

Af­ter in­sid­er trad­ing scan­dal, US con­gress­man drops cam­paign — but stays on the bal­lot; Jun­shi Bio­sciences ap­plies ...

7 years ago
News Briefing

Back to the be­gin­ning: Pfiz­er seeds dis­cov­ery-stage neu­ro start­up Mag­no­lia (af­ter ax­ing its own brain R&D)

7 years ago
Financing
Startups

Af­ter mixed pipeline up­dates, Re­genXBio to raise $175M in of­fer­ing; Bio­Elec­tron clos­es $40M to prep late-stage ...

7 years ago
News Briefing

Once a multi­bil­lion dol­lar com­pa­ny, Ova­Science ends a pen­ny­s­tock ve­hi­cle for Mil­len­do's re­verse merg­er

7 years ago
Deals

Tap­ping Chi­nese in­vestors, Apex­i­gen clos­es $73M for 8 tri­als in I/O

7 years ago
Financing
Startups

In­sid­er trad­ing in Wash­ing­ton: NY Con­gress­man in­dict­ed for shar­ing in­side biotech tips ahead of mas­sive tri­al fail­ure

7 years ago
People

Prof­its sink­ing, My­lan looks to strate­gic al­ter­na­tives; No­vo posts de­press­ing Q2

7 years ago
News Briefing
1234 Next page Last page
A service from the Financial Times